Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Press

Showing results (121-130 of 273) with videos related to

Pageof 28
Sort By:
Geburtshilfe Und Frauenheilkunde|April 1, 1995
[Prognostic differentiation of ovarian carcinomas by immunohistochemical analysis of estrogen receptor expression]D G Kieback, M F Press, S K McCamant, et al.
Clinical Breast Cancer|March 21, 2009
A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approachCarolyn D Britten, Richard S Finn, Linda D Bosserman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2010
Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancerLeona Downey, Robert B Livingston, Maria Koehler, et al.
Anticancer Research|November 1, 1993
Prognostic significance of estrogen receptor expression in ovarian cancer. Immunoreactive Score (IRS) vs. Composition Adjusted Receptor Level (CARL)D G Kieback, M F Press, E N Atkinson, et al.
The American Journal of Pathology|January 1, 1997
WAF1/Cip1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometriumJ Lukas, S Groshen, B Saffari, et al.
Cancer Research|November 1, 1993
Improved prediction of survival in advanced adenocarcinoma of the ovary by immunocytochemical analysis and the composition adjusted receptor level of the estrogen receptorD G Kieback, S K McCamant, M F Press, et al.
Cancer Research|October 15, 1993
Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent diseaseM F Press, M C Pike, V R Chazin, et al.
Science (New York, N.Y.)|June 21, 1985
Studies of the putative transforming protein of the type I human T-cell leukemia virusD J Slamon, M F Press, L M Souza, et al.
Oncotarget|February 4, 2016
Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cellsMaria C Palanca-Wessels, Garrett C Booth, Anthony J Convertine, et al.
Neurosurgery|October 1, 1989
Estrogen and progesterone receptors in meningiomas: comparison of nuclear binding, dextran-coated charcoal, and immunoperoxidase staining assaysJ Halper, D S Colvard, B W Scheithauer, et al.
Pageof 28

Showing results (121-130 of 273) with videos related to

Sort By:
Pageof 28
Geburtshilfe Und Frauenheilkunde|April 1, 1995
[Prognostic differentiation of ovarian carcinomas by immunohistochemical analysis of estrogen receptor expression]D G Kieback, M F Press, S K McCamant, et al.
Clinical Breast Cancer|March 21, 2009
A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approachCarolyn D Britten, Richard S Finn, Linda D Bosserman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2010
Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancerLeona Downey, Robert B Livingston, Maria Koehler, et al.
Anticancer Research|November 1, 1993
Prognostic significance of estrogen receptor expression in ovarian cancer. Immunoreactive Score (IRS) vs. Composition Adjusted Receptor Level (CARL)D G Kieback, M F Press, E N Atkinson, et al.
The American Journal of Pathology|January 1, 1997
WAF1/Cip1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometriumJ Lukas, S Groshen, B Saffari, et al.
Cancer Research|November 1, 1993
Improved prediction of survival in advanced adenocarcinoma of the ovary by immunocytochemical analysis and the composition adjusted receptor level of the estrogen receptorD G Kieback, S K McCamant, M F Press, et al.
Cancer Research|October 15, 1993
Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent diseaseM F Press, M C Pike, V R Chazin, et al.
Science (New York, N.Y.)|June 21, 1985
Studies of the putative transforming protein of the type I human T-cell leukemia virusD J Slamon, M F Press, L M Souza, et al.
Oncotarget|February 4, 2016
Antibody targeting facilitates effective intratumoral siRNA nanoparticle delivery to HER2-overexpressing cancer cellsMaria C Palanca-Wessels, Garrett C Booth, Anthony J Convertine, et al.
Neurosurgery|October 1, 1989
Estrogen and progesterone receptors in meningiomas: comparison of nuclear binding, dextran-coated charcoal, and immunoperoxidase staining assaysJ Halper, D S Colvard, B W Scheithauer, et al.
Pageof 28